Litifilimab Lessens Skin Disease Activity in Lupus, Trial Data Show
Biogen’s experimental therapy litifilimab, also called BIIB059, significantly reduced skin disease activity in adults with cutaneous lupus erythematosus (CLE), according to data from part B of the Phase 2 LILAC trial. CLE is a type of lupus that’s also known as skin lupus. As its name suggests, skin…